Galectin Therapeutics (NASDAQ:GALT – Get Free Report) and Nanobiotix (NASDAQ:NBTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.
Insider and Institutional Ownership
11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Galectin Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Galectin Therapeutics | N/A | N/A | -$30.84 million | ($0.41) | -6.37 |
| Nanobiotix | $36.87 million | 50.01 | -$27.11 million | N/A | N/A |
Nanobiotix has higher revenue and earnings than Galectin Therapeutics.
Profitability
This table compares Galectin Therapeutics and Nanobiotix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Galectin Therapeutics | N/A | N/A | -164.69% |
| Nanobiotix | N/A | N/A | N/A |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Galectin Therapeutics and Nanobiotix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Galectin Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Nanobiotix | 1 | 1 | 4 | 0 | 2.50 |
Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 321.46%. Nanobiotix has a consensus target price of $26.67, suggesting a potential downside of 29.82%. Given Galectin Therapeutics’ higher probable upside, research analysts clearly believe Galectin Therapeutics is more favorable than Nanobiotix.
Summary
Nanobiotix beats Galectin Therapeutics on 7 of the 9 factors compared between the two stocks.
About Galectin Therapeutics
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
About Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
